1-7 of 7
Tadeusz Kubicki
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Clinical Trials & Observations
Tadeusz Kubicki, Dominik Dytfeld, David Barnidge, Dhananjay Sakrikar, Anna Przybyłowicz-Chalecka, Krzysztof Jamroziak, Paweł Robak, Jarosław Czyż, Agata Tyczyńska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Wróbel, Adam Nowicki, Tomasz Szczepaniak, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Łukasz Szukalski, Agnieszka Końska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Ken Jiang, Jennifer H. Cooperrider, Andrzej J. Jakubowiak, Benjamin A. Derman
Journal: Blood
Blood (2024) 144 (9): 955–963.
https://doi.org/10.1182/blood.2024024041
Published: 2024
Includes: Supplemental data
Journal Articles

Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

Ben A Derman, Tadeusz Kubicki, Heidi Simmons, Aimaz Afrough, Jeffrey A. Zonder, David L. Grinblatt, Larry D. Anderson, Jr., Andrew Kin, Sunil Narula, Shayan Rayani, Sandeep Gurbuxani, Theodore Karrison, Ken Jiang, Ajay Major, Jennifer H Cooperrider, Allison P. Jacob, Andrzej J Jakubowiak
Journal: Blood
Blood (2023) 142 (Supplement 1): 1982.
https://doi.org/10.1182/blood-2023-182410
Published: 2023
Journal Articles

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Tadeusz Kubicki, Dominik Dytfeld, Tomasz Wrobel, Krzysztof Jamroziak, Pawel Robak, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Adam Nowicki, Tomasz Szczepaniak, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Michal Pula, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Lukasz Szukalski, Agnieszka Konska, Jan M. Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Dorota Kruk-Kwapisz, Oscar Boutros Lahoud, Jeffrey A. Zonder, Kent Griffith, Andrew T Stefka, Ken Jiang, Jennifer H Cooperrider, Ben A Derman, Andrzej J Jakubowiak
Journal: Blood
Blood (2023) 142 (Supplement 1): 4715.
https://doi.org/10.1182/blood-2023-189850
Published: 2023
Journal Articles

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Tadeusz Kubicki, Ben A Derman, Krzysztof Jamroziak, Pawel Robak, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Wrobel, Adam Nowicki, Tomasz Szczepaniak, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Michal Pula, Lukasz Szukalski, Agnieszka Konska, Jan M. Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Dorota Kruk-Kwapisz, Andrzej J Jakubowiak, Dominik Dytfeld
Journal: Blood
Blood (2023) 142 (Supplement 1): 3344.
https://doi.org/10.1182/blood-2023-189537
Published: 2023
Journal Articles

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Tadeusz Kubicki, Dominik Dytfeld, David Barnidge, DJ Sakrikar, Gabriella Lakos, Anna Przybylowicz-Chalecka, Krzysztof Jamroziak, Pawel Robak, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Wrobel, Adam Nowicki, Tomasz Szczepaniak, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Michal Pula, Lukasz Szukalski, Agnieszka Konska, Jan M. Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Ken Jiang, Jennifer H Cooperrider, Andrzej J Jakubowiak, Benjamin A Derman
Journal: Blood
Blood (2023) 142 (Supplement 1): 340.
https://doi.org/10.1182/blood-2023-190209
Published: 2023
Journal Articles

Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)

Benjamin A Derman, Jennifer H Cooperrider, Jacalyn Rosenblatt, David Avigan, Murtuza M. Rampurwala, Ajay Major, Theodore Karrison, Ken Jiang, Tadeusz Kubicki, Andrzej J Jakubowiak
Journal: Blood
Blood (2023) 142 (Supplement 1): 4747.
https://doi.org/10.1182/blood-2023-185309
Published: 2023
Journal Articles

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Clinical Trials & Observations
Jagoda K. Jasielec, Tadeusz Kubicki, Noopur Raje, Ravi Vij, Donna Reece, Jesus Berdeja, Benjamin A. Derman, Cara A. Rosenbaum, Paul Richardson, Sandeep Gurbuxani, Sarah Major, Brittany Wolfe, Andrew T. Stefka, Leonor Stephens, Kathryn M. Tinari, Tyler Hycner, Alexandra E. Rojek, Dominik Dytfeld, Kent A. Griffith, Todd M. Zimmerman, Andrzej J. Jakubowiak
Journal: Blood
Blood (2020) 136 (22): 2513–2523.
https://doi.org/10.1182/blood.2020007522
Published: 2020
Includes: Supplemental data